|
|
||||||||

The1 Wistar Institute of Anatomy and Biology, 3601 Spruce Street, Philadelphia, Pennsylvania 19104-4268, U.S.A.
2 National Institute of Dental Research, 9000 Rockville Pike, Bethesda, Maryland 20892, U.S.A.
3 Institut Pasteur, Merieux, 1541 Avenue Marcel-Merieux, 69280 Marcy-l'Etoile, France
and4 Virogenetics Corporation, Rensselaer Technology Park, 465 Jordan Road, Troy, New York 12180, U.S.A.
A murine model of the cytotoxic T lymphocyte (CTL) response to glycoprotein B (gB) of human cytomegalovirus (HCMV) was developed based on the use of adenovirus (Ad) and vaccinia virus (Vac) recombinants expressing gB. Mice of different major histocompatibility haplotypes [CBA (H-2k), BALB/k (H-2k) and BALB/c (H-2d)] infected with the Ad-gB recombinant developed an Ad-specific CTL response. However, only the H-2k mice developed a significant HCMV gB-specific CTL response, as indicated by the major histocompatibility complex class I-restricted lysis of Vac strain Copenhagen (VacC)-gB recombinant-infected target cells by H-2k mouse immune spleen cells. The VacC-gB recombinant elicited only a weak gB-specific CTL response in these mice, indicating that the observed gB-specific CTL response in mice is dependent on the expression vector used for immunization. The gB-specific cytotoxicity observed in H-2k mice was mediated by the CD8 lymphocyte subset.
Present address: Triplex Pharmaceutical Corporation, 9391 Grogen's Mill Road, The Woodlands, Texas 77380, U.S.A.
Received 1 June 1993;
accepted 20 July 1993.
This article has been cited by other articles:
![]() |
Z. Wang, C. La Rosa, R. Maas, H. Ly, J. Brewer, S. Mekhoubad, P. Daftarian, J. Longmate, W. J. Britt, and D. J. Diamond Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human Cytomegalovirus J. Virol., April 15, 2004; 78(8): 3965 - 3976. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gallez-Hawkins, M. C. Villacres, X. Li, M. C. Sanborn, N. A. Lomeli, and J. A. Zaia Use of Transgenic HLA A*0201/Kb and HHD II Mice To Evaluate Frequency of Cytomegalovirus IE1-Derived Peptide Usage in Eliciting Human CD8 Cytokine Response J. Virol., April 1, 2003; 77(7): 4457 - 4462. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |